Drug Trial Radar · NCT04901741
Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 2026
Primary completion
Mar 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- TME Pharma AGIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- May 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide a go/no-go decision for a randomized expansion study by assessing the disease control rate (DCR) at 6 weeks for the combination of olaptesed pegol on top of pembrolizumab and (Arm 1) nanoliposomal irinotecan, 5-FU and leucovorin or (Arm 2) gemcitabine and nab-paclitaxel, to assess safety and tolerability and time-to-event endpoints.
Conditions
- Metastatic Pancreatic Cancer
Interventions
Olaptesed pegolDrug
400 mg per week as continous infusion until progression or intolerable toxicity
PembrolizumabDrug
200 mg every 3 weeks as i.v. infusion until progression or intolerable toxicity or a maximum of 35 administrations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Go/no-go decision for a randomized expansion studyTime frame: until progression or intolerable toxicity to completion of 35 administrations (approximately 2 years) with pembrolizumab
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.